| 0.661 -0.209 (-24.02%) | 04-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.8 | 1-year : | 1.12 |
| Resists | First : | 0.69 | Second : | 0.96 |
| Pivot price | 0.52  |
|||
| Supports | First : | 0.25 | Second : | 0.2 |
| MAs | MA(5) : | 0.3 |
MA(20) : | 0.5 |
| MA(100) : | 7.8 |
MA(250) : | 11.05 |
|
| MACD | MACD : | -0.5  |
Signal : | -0.6 |
| %K %D | K(14,3) : | 6.5 |
D(3) : | 5.1 |
| RSI | RSI(14): 29.5 |
|||
| 52-week | High : | 18.2 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACOR ] has closed above bottom band by 20.5%. Bollinger Bands are 82.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.3 - 0.3 | 0.3 - 0.3 |
| Low: | 0.3 - 0.3 | 0.3 - 0.3 |
| Close: | 0.3 - 0.3 | 0.3 - 0.3 |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Wed, 03 Apr 2024
Acorda Therapeutics Announces Nasdaq Delisting Notification - Business Wire
Tue, 02 Apr 2024
Acorda Therapeutics’ Strategic Bankruptcy and Asset Sale Plan - TipRanks
Tue, 02 Apr 2024
Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today? - InvestorPlace
Mon, 01 Apr 2024
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement - Business Wire
Mon, 18 Dec 2023
Moderna (MRNA) and Acorda Therapeutics (ACOR): Buy, Hold, or Sell in 2024? - StockNews.com
Fri, 24 Nov 2023
VRTX: 3 Safe Biotech Stocks to Buy This Week - StockNews.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 13.2 (%) |
| Shares Short | 8 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | -203.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -127.17 |
| Profit Margin | -215 % |
| Operating Margin | 3.9 % |
| Return on Assets (ttm) | -5.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 20.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 94.86 |
| EBITDA (p.s.) | 6.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | 20 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|